Utility of the PROSTest, a Novel Blood-Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease.
Mark Kidd, Grzegorz Rempega, Michal Kepinski...
https://pubmed.ncbi.nlm.nih.gov/41129487/Actively Recruiting
Led by Wren Laboratories LLC · Updated on 2026-08-21
1500
Participants Needed
1
Research Sites
13 weeks
Total Duration
Researchers are conducting a prospective observational study to evaluate the diagnostic performance of PROSTest in men referred for prostate biopsy due to elevated PSA levels andor abnormal digital rectal examination. This study focuses on men aged 45 to 80 years and aims to compare PROSTest results with biopsy histopathology, the current standard for prostate cancer diagnosis. Participants will provide a peripheral blood sample before undergoing prostate biopsy. PROSTest analysis will be performed on these blood samples without knowledge of the biopsy results to ensure unbiased evaluation. The study will calculate diagnostic accuracy measures such as sensitivity, specificity, negative predictive value, and the area under the receiver operating characteristic curve. Additionally, the study will explore how PROSTest scores relate to MRI findings and pathologic grade groups. During the study, men will undergo blood collection and prostate biopsy as part of their clinical care. Researchers will analyze PROSTest diagnostic accuracy and secondary metrics after study completion, expected within 18 months. The study plans to enroll about 1,500 participants and monitor outcomes to assess PROSTests potential to reduce unnecessary biopsies and improve diagnostic decisions.
CONDITIONS
A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth
M
Mark Kidd, PhD
T
Tracy Auster, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Wren Laboratories LLC
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 18 months
Participants provide a blood sample for PROSTest analysis before undergoing prostate biopsy as part of their clinical care.
Blood collection and biopsy as scheduled by clinical care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Mark Kidd, Grzegorz Rempega, Michal Kepinski...
https://pubmed.ncbi.nlm.nih.gov/41129487/Kambiz Rahbar, Mark Kidd, Vikas Prasad...
https://pubmed.ncbi.nlm.nih.gov/39838708/Craig G Rogers, Srinivas V Koduru, Anthony Gulati...
https://pubmed.ncbi.nlm.nih.gov/41463159/Kambiz Rahbar, R David Rosin, Mark Kidd...
https://pubmed.ncbi.nlm.nih.gov/40970770/Wren Laboratories LLC
Lead Sponsor